This project is part of the EU funded project “individualized paediatric cure- iPC” that aims to find novel therapeutic routes for children with cancer. Researchers will carry out this work based on systems biological analysis and modeling of large scale genomic, transcriptomic and proteomic data sets. This makes this project a very comprehensive review of cancer systems. Data from patients with high grade gliomas will be made accessible to researchers through the Pediatric Brain Tumor Atlas. Researchers will model drug responses of an initial cohort of ~20 patients using a computer model to find potential drug treatments for high grade glioma patients. The information gained from this work will advance treatment options for patients with pediatric high grade gliomas.
What are the goals of this project?
Researchers will model drug responses to find potential new treatment options for high grade glioma patients.
What is the impact of this project?
High grade gliomas are hard to treat, but this work could identify new avenues for effective treatments.
Why is the CBTN request important to this project?
This comprehensive research is made possible through the provision of rare data on high grade gliomas from the Pediatric Brain Tumor Atlas.
The Children's Brain Tumor Network contributed to this project by providing access to the Pediatric Brain Tumor Atlas.
Adam Resnick, PhD
Adam Resnick is the Director of Data Driven Discovery in Biomedicine (D3b) at Children’s Hospital of Philadelphia (CHOP) responsible for leading a multidisciplinary team to build and support a scalable, patient-focused healthcare and educational discovery ecosystem on behalf of all children. He is a
Children’s Hospital of Philadelphia
Children’s Hospital of PhiladelphiaJoined on
Operations Center for the Children’s Brain Tumor Tissue Consortium, the Children’s Hospital of Philadelphia (CHOP) is currently ranked 1st nationally for their Pediatric Cancer Program by U.S. News & World Report. CHOP’s Biobank is home to the CBTTC’s pediatric brain and CNS tumor biorepository; the
High-grade Gliomas (HGG) or astrocytomas in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric-specific HGG preclinical models. These models are needed to help test